Semaglutide in India
CDSCO-registered Ozempic + Rybelsus since 2022; Wegovy launch in progress 2025-2026 with first-wave generic semaglutide approvals September-December 2025. Premium private hospital routes (Apollo, Fortis, Manipal) are the trustworthy lane; CDSCO has issued misuse advisories on grey-market sales.
CDSCO-registered for Ozempic, Rybelsus, and Wegovy (rolling launch). Prescription-only. Generic semaglutide approvals began Sep 2025; brand discount is significant. CDSCO advisories on grey-market GLP-1 sales make hospital channel mandatory for trust.
What it actually costs.
Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.
Per month at typical maintenance dose. Cheaper than Wegovy when it launches; Ozempic is the established route for off-label weight prescribing.
Per month including endo consult. Wegovy supply still ramping in 2026.
Per month. First-wave Indian generic approvals September-December 2025; pricing in flux. Quality varies — only buy through hospital channel.
How to get it — on the right side of the line.
Apollo Pharmacy + Apollo Hospitals consult
Apollo Pharmacy publishes the 'How to Buy Wegovy in India' guide and stocks Ozempic and Rybelsus. Apollo Sugar Clinics is the dedicated Apollo+Sanofi diabetes & endocrinology specialty network across 6+ cities, 87% HbA1c-control claim.
Fortis or Manipal hospital network
Fortis C-DOC (Diabetes & Endocrinology Centre of Excellence). Manipal Bhubaneshwar publishes a public Ozempic vs Mounjaro decision-tree blog — most explicit GLP-1 protocol page among Indian hospital chains.
Generic semaglutide (post-Sep 2025)
Indian-manufactured generics began approval cycle September 2025. Significant cost savings vs brand. Hospital channel only — ask your endocrinologist which generic they trust; quality variance across manufacturers.
What channels actually work here.
Ozempic / Rybelsus established; Wegovy rolling out 2025-2026.
Indian compounding regulatory is less mature than the US; not a recommended path.
CDSCO advisories active.
Apollo + Manipal hybrid telehealth.
India's semaglutide market is in flux. Generic approvals (Sep-Dec 2025) will drop pricing further over 2026. For now: Ozempic via Apollo is the established route. For users prioritising Wegovy specifically, wait until late-2025 launch is fully active or route through Apollo Pharmacy's Wegovy guide.
What's actually in stock right now.
Per-brand stock state for semaglutide in this region, sourced from cohort research and operator feedback. Each entry has a verifiedAt date so you can judge freshness. Confirm at the specific provider before booking.
Wegovy launch is rolling out late-2025/2026. Stock at premium hospitals (Apollo, Fortis, Manipal); supply still ramping.
Established T2D channel. Off-label weight prescribing common via hospital chains. Most reliable semaglutide route in India.
Oral semaglutide. Apollo Pharmacy stocks. Niche fit.
Tirzepatide in India
Mounjaro / Zepbound — dual GLP-1 + GIP agonist. Eli Lilly. Stronger weight effect head-to-head than semaglutide; also more expensive and supply has been more constrained globally.
Match me to a vendor in India.
Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.